Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbCellera Biologics Inc (ABCL) vs Aecom (ACM) Price & Performance

AbCellera Biologics IncTrade

Price performance (Past 24H)

Key statistics

AbCellera Biologics Inc vs Aecom — how do they compare? AbCellera Biologics Inc trades at $8.93 (market cap $2.85B), while Aecom trades at $66.76 (market cap $9.42B). The key difference: Aecom is far larger — about 3.3× AbCellera Biologics Inc's market cap, and Aecom pays a 1.62% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.

ABCLACM
Market Cap
$2.85B$9.42B
Sector
HealthIndustrials
52-Week High
$9.76$134.35
52-Week Low
$2.78$66.86
Enterprise Value
$2.45B$11.60B
Dividend Yield
1.62%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbCellera Biologics Inc

ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.

The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.

Aecom

ACM trades at $75.84, up 1.21% daily, with a bullish technical signal from moving averages and ADX indicators. Recent Q2 2026 earnings missed expectations with a loss of $0.50 per share, though revenue trends remain stable near $16 billion annually. The company secured new infrastructure projects in Australia and Portugal, supporting a record backlog. Valuation metrics show a P/E of 15.83 and P/S of 0.63, below sector averages, indicating potential undervaluation.

Outlook is mixed: strong analyst consensus (64% buy) and a $99.20 price target suggest 31% upside, but Q2 miss and rising debt-to-asset ratio (22.61% in 2025) pose risks. Investors should weigh robust contract wins against earnings volatility and macroeconomic pressures on infrastructure spending.

Returns comparison

Trailing returns across standard periods

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Read more on ABCL

About Aecom

Aecom is one of the largest global providers of design, engineering, construction, and management services. The firm serves a broad spectrum of end markets including infrastructure, water, transportation, and energy. Based in Los Angeles, Aecom has a presence in over 150 countries and employs 51,000. The company generated $13.3 billion in sales and $701 million in adjusted operating income in fiscal 2021.

Read more on ACM